DermTech Announces Health Canada Approval
DermTech, Inc., the global leader in non-invasive molecular dermatology, announced today that its licensee, DermTech Canada Inc. has received approval to market DermTech’s Pigmented Lesions Assay (PLA) and non-invasive biopsy kit for the detection of melanoma in Canada. DermTech Canada will market and sell the PLA, and samples will be processed at DermTech’s central laboratory in La Jolla, California. Provincial coverage approvals are in process, initially focused on British Columbia and Ontario, and are expected to expand across Canada.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180104005191/en/
“Health Canada’s approval of the license to market our assay in Canada is a further validation of the utility of our cancer detection platform and a strong statement about the potential demand for a non-invasive alternative to surgical biopsies. We will be working closely with our Canadian licensee to leverage our sales and marketing expertise ensuring a successful launch across Canada,” stated Dr. John Dobak, CEO of DermTech, Inc.
“We are very excited to receive such rapid approval from Health Canada and are enthusiastic about our upcoming Canada-wide launch to bring DermTech’s important new cancer diagnostic to Canadian patients. We look forward to working closely with the DermTech US team to make this roll-out a success,” said Douglas Horne, CEO of DermTech Canada Inc.
About DermTech
DermTech is the global leader in molecular dermatology, bringing precision medicine to the diagnosis and treatment of skin disease. We market and develop products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. DermTech analyzes skin biopsy samples collected non-invasively using an adhesive patch rather than a scalpel. Our mission is to transform dermatology by delivering highly accurate and objective information to the clinician to improve care and reduce costs and to pharma partners to support the development of targeted therapeutics. For additional information visit: dermtech.com.
About DermTech Canada
DermTech Canada is licensed to sell DermTech’s products in the Canadian market. For more information visit: dermtech.ca.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180104005191/en/
DermTech, Inc.
Sarah Dion, MBA
VP, Sales and Marketing
(858)
450-4222
sdion@dermtech.com
or
DermTech
Canada Inc.
Douglas Horne
President & CEO
1-888-519-1226
dhorne@dermtech.ca
